A β -Induced Insulin Resistance and the Effects of Insulin on the Cholesterol Synthesis Pathway and A β Secretion in Neural Cells

Dema Najem^{1,2} · Michelle Bamji-Mirza^{1,2} · Ze Yang³ · Wandong Zhang^{1,2}

Received: 14 October 2015 / Accepted: 21 April 2016 / Published online: 20 May 2016
© Shanghai Institutes for Biological Sciences, CAS and Springer Science+Business Media Singapore 2016

Abstract Alzheimer's disease (AD) is characterized by amyloid- β (A β) toxicity, tau pathology, insulin resistance, neuroinflammation, and dysregulation of cholesterol homeostasis, all of which play roles in neurodegeneration. Insulin has polytrophic effects on neurons and may be at the center of these pathophysiological changes. In this study, we investigated possible relationships among insulin signaling and cholesterol biosynthesis, along with the effects of A β_{42} on these pathways *in vitro*. We found that neuroblastoma 2a (N2a) cells transfected with the human gene encoding amyloid- β protein precursor (A β PP) (N2a-A β PP) produced A β and exhibited insulin resistance by reduced p-Akt and a suppressed cholesterol-synthesis pathway following insulin treatment, and by increased phosphorylation of insulin receptor subunit-1 at serine 612 (p-IRS-S612) as compared to parental N2a cells. Treatment of human neuroblastoma SH-SY5Y cells with A β_{42} also increased p-IRS-S612, suggesting that A β_{42} is responsible for insulin resistance. The insulin resistance was alleviated when N2a-A β PP cells were treated with higher insulin concentrations. Insulin increased A β release from N2a-A β PP cells, by which it may promote A β clearance. Insulin increased cholesterol-synthesis gene expression in SH-SY5Y and N2a cells, including 24-dehydrocholesterol reductase (DHCR24) and 3-hydroxy-3-methyl-glutaryl-

CoA reductase (HMGCR) through sterol-regulatory element-binding protein-2 (SREBP2). While A β_{42} -treated SH-SY5Y cells exhibited increased HMGCR expression and c-Jun phosphorylation as pro-inflammatory responses, they also showed down-regulation of neuro-protective/anti-inflammatory DHCR24. These results suggest that A β_{42} may cause insulin resistance, activate JNK for c-Jun phosphorylation, and lead to dysregulation of cholesterol homeostasis, and that enhancing insulin signaling may relieve the insulin-resistant phenotype and the dysregulated cholesterol-synthesis pathway to promote A β release for clearance from neural cells.

Keywords Alzheimer's disease · Insulin resistance · A β peptides · Insulin signaling · Cholesterol synthesis pathway · Pro-inflammatory response

Introduction

Alzheimer's disease (AD) is a progressive, age-related neurodegenerative disorder of the brain. It is the most common form of dementia that is incurable and terminal [1]. The prevalence of the disorder is increasing at an alarming rate, afflicting ~30 million people worldwide and is expected to quadruple by 2050 [2]. The neuropathological characteristics of AD include the presence of senile plaques, defective brain insulin signaling [3], dysregulated cholesterol homeostasis [4], decreased glucose utilization, increased oxidative stress, and inflammation leading to neurodegeneration [5]. The plaques are composed mostly of aggregated amyloid- β 40 (A β_{40}) and A β_{42} peptides, which are derived by proteolysis of the amyloid- β precursor protein (A β PP) [6, 7]. In the amyloidogenic pathway, A β PP is cleaved by β -secretase (also

✉ Wandong Zhang
Wandong.Zhang@nrc.ca; wzhan2@uottawa.ca

¹ Faculty of Medicine, University of Ottawa, Ottawa, ON K1H8M5, Canada

² Human Health Therapeutics, National Research Council of Canada, Ottawa, ON K1A0R6, Canada

³ Beijing Hospital, Institute of Geriatrics-Chinese Health Ministry, Beijing 100730, China

known as β -site A β PP-cleaving enzyme 1), releasing sA β PP $_{\beta}$ while retaining C99 within the membrane. The γ -secretase complex then cleaves C99 to produce A β_{40} and A β_{42} [8]. In AD, the production, accumulation, and aggregation of A β are considered to be the initial steps to neurodegeneration and a critical part of the progression of the disease [9]. A β_{42} plays a more pivotal role in the pathogenesis of AD than A β_{40} due to its higher aggregative ability [10, 11].

Recently, insulin resistance and insulin signaling deficiency have been considered important features in the progression of AD. Insulin is an important regulator of brain cell function and metabolism. It affects neuronal synaptic function and plasticity, and glucose/lipid/cholesterol metabolism in the brain [12]. Several studies have shown clinical correlations between the failure of signals in the insulin pathways and brain disorders including stroke, AD, and Parkinson's disease [13]. Impairments of insulin signaling have not only been described in human AD, but also in animal models of AD [14, 15] and in rodents receiving intracerebral streptozotocin injections [16]. Lower levels of insulin and insulin receptors (IRs) in AD brains further implicate insulin resistance in the neuropathology [17, 18]. One way to visualize insulin signaling in cells is to examine the phosphorylation of downstream signaling proteins such as pAkt-S473 and IR substrate 1 (IRS-1) at Y895 [19, 20]. IRS-1 contains multiple tyrosine-phosphorylation motifs and they mediate the metabolic and growth-promoting function of insulin [21–23]. IRS-1 also contains serine/threonine phosphorylation sites, such as IRS-1-S612, that when phosphorylated results in an inhibition of insulin signaling in the cell [24, 25] and may indicate insulin resistance [26].

Another recognized feature of AD is the dysregulation of cholesterol and lipid homeostasis in the brain [4]. Such dysregulation may increase A β production [4], and several studies have linked cholesterol, lipid, and lipoprotein dysregulation to the insulin-resistant state [27]. One study attributed the link between cognitive deficits in diabetic rodents and the impaired regulation of cholesterol synthesis in the brain to insulin resistance [28]. Insulin activates the transcription factors sterol-regulatory element-binding proteins (SREBPs), which are involved in cholesterol and fatty-acid synthesis [28]; SREBP1a and SREBP1c regulate fatty-acid synthesis while SREBP2 is specific for cholesterol biosynthesis [29–32]. There are two key enzymes along the cholesterol biosynthesis pathway, HMGCR (3-hydroxy-3-methylglutaryl-CoA reductase), the rate-limiting enzyme of cholesterol biosynthesis, and DHCR24 (24-dehydrocholesterol reductase), catalyze the last step of cholesterol synthesis. The mechanisms of insulin resistance in the context of A β production and cholesterol metabolism in AD progression are not completely understood. In this study, we investigated the interplay between insulin

resistance, cholesterol metabolism, and A β production *in vitro* in N2a, N2a-A β PP, and SH-SY5Y cells. We showed that A β_{42} peptides can cause insulin-resistance phenotypes in N2a-A β PP and SH-SY5Y cells, and that treatment of the cells with insulin increases the expression of cholesterol synthesis genes and A β secretion.

Materials and Methods

Chemical Reagents

Dulbecco's modified Eagle's medium (DMEM), TRIzol, geneticin, 0.25% trypsin/EDTA, and gentamycin were from Life Technologies Inc. (Burlington, ON, Canada). Fetal bovine serum (FBS) was from Hyclone (Logan, UT, USA). Hank's balanced salt solution (HBSS) was from Wisent Multicell (Montreal, QC, Canada). Dimethyl sulfoxide (DMSO), recombinant human insulin, protease inhibitor cocktail, bovine serum albumin (BSA), and penicillin-streptomycin were from Sigma Aldrich Canada Ltd. (Oakville, ON, Canada). Eagle's minimum essential medium (EMEM) was from ATCC (Manassas, VA, USA). Ham's F12 medium was from Cellgro (Manassas, VA, USA). The BSA standard, Experion RNA StdSens analysis kit, SsoFast EvaGreen Supermix, iScript cDNA synthesis kit, and PVDF membranes were from Bio-Rad (Hercules, CA, USA). Recombinant A β_{42} and scrambled A β_{42} peptide (A β_{42} sc), with the same amino-acids as A β_{42} but in a randomized order, were from r-Peptide Inc. (Bogart, GA, USA). The sequences of A β_{42} and A β_{42} sc were DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA and KVKGLIDGAHIGDLVYEFMDSNSAIFREGVGAGHVVHVAQVEF, respectively. Antibodies for β -actin, total c-Jun, phospho c-Jun S63, phospho IRS-1 (S612), phospho IRS-1 (Y895), total IRS, total AKT, phospho AKT (S473), and DHCR34/seladin-1 were from New England Biolabs (Pickering, ON, Canada). SREBP2 and HMGCR antibodies were from Abcam (Cambridge, MA, USA). Western-Lighting Plus-ECL was from Perkin Elmer Inc. (Waltham, Massachusetts, USA). Autoradiography film was from Mandel Scientific (Guelph, ON, Canada).

Cell Cultures

Immortalized, undifferentiated human SH-SY5Y cells were maintained in EMEM: Ham's F12 (1:1) supplemented with 10% FBS and 1% gentamycin at 37°C and 5% CO₂. Immortalized mouse neuroblastoma 2a cells (N2a) and these cells stably transfected with human A β PP695 gene (N2a-A β PP) were grown in EMEM:DMEM (1:1) supplemented with 5% FBS and 1% penicillin-streptomycin [4].

Geneticin was added to the N2a-A β PP medium to select for cells carrying the A β PP gene.

Insulin and A β_{42} Treatment

Cells were plated in 60-mm dishes at 70% density in serum-deficient medium (to exclude the effects of serum insulin on the cells). Human recombinant insulin was solubilized in sterile water at pH 2, following the manufacturer's instructions. Cells were treated, 24 h after plating, with insulin at varying concentrations and for different treatment times. Negative control cells were treated with the vehicle solution (sterile water at pH 2). A β_{42} and A β_{42} sc were reconstituted to 400 mmol/L in 0.25% sterile acetic acid, following the manufacturer's instructions. SH-SY5Y cells were treated, 24 h after plating, with 5 μ mol/L A β_{42} or A β_{42} sc for different times. Negative control cells were treated with A β_{42} vehicle (0.25% sterile acetic acid).

Protein Isolation and Western Blotting

After treatment, the cells were washed twice with HBSS and lysed with western loading buffer (5% glycerol, 5% β -mercaptoethanol, 3% SDS, 0.03% bromophenol blue, 10 nmol/L Tris-HCl). The lysates were boiled at 100°C for 10 min, cooled on ice for 5 min, and spun at 14000 rpm for 15 min. The supernatant containing the solubilized proteins was transferred to new tubes and total protein levels were determined by the trichloroacetic acid assay. Proteins (15 μ g) were resolved on 10% SDS-PAGE gels and transferred onto PVDF membrane. The blots were incubated in blocking buffer [5% skim milk powder in 1 $\times$ Tris-buffered saline Tween 20 (TBST) or filtered 3% BSA powder in 1 $\times$ TBST] at room temperature for 1–2 h. The blots were incubated with a primary antibody at 1:1000 dilution overnight at 4°C, washed with 1 $\times$ TBST, incubated with an appropriate

secondary antibody at 1:5000 dilution, and the protein bands were visualized with ECL Plus solution on X-ray film. The bands were analyzed using UN-SCAN-IT gel 6.1 software (Silk Scientific Inc., Orem, Utah) for densitometry and the treated samples were compared to controls by calculating the fold-change of treated sample to vehicle.

Enzyme-Linked Immunosorbent Assay (ELISA)

The A β_{40} and A β_{42} ELISA kits were from Life Technologies Inc. (Burlington, ON, Canada). Media from N2a-A β PP cells were harvested and stored at –80°C. Samples were centrifuged at 200 rpm to remove cell debris, and diluted 1:2 using the provided buffer supplemented with protease inhibitor cocktail to prevent protein degradation. Standards and samples were prepared as per the instructions with the kit. Results were normalized to the protein content of cells and are presented relative to vehicle.

RNA Isolation and Quantitative Polymerase Chain Reaction (QPCR)

Total RNA was isolated from treated cells using TRIzol reagent, following the manufacturer's instructions. Genomic DNA was removed from the samples using Ambion DNA-free kits, following the manufacturer's instructions (Life Technologies, Burlington, ON, Canada). The concentration of RNA in each sample was determined using a NanoDrop 1000 UV–Vis Spectrophotometer (Thermo Scientific Inc., Nepean, ON, Canada). The RNA integrity was checked using an Experion Automated Electrophoresis System from Bio-Rad (Berkeley, CA, USA). The mRNA was transcribed into cDNA using iScript kits, following the manufacturer's instructions. The QPCR primers were from IDT (Coralville, IA, USA; Table 1). Mixtures consisting of 10 μ L Ssofast Eva Green Supermix (Bio-Rad), 2 μ L of cDNA sample at 1/10 dilution (determined

Table 1 Primer sequences of genes involved in cholesterol synthesis.

Gene		Sequences		
Hs. DHCR24	Human	Forward	5'-CTTGCTACCCTGCTCCTTC-3'	
		Reverse	5'-CGCTCTCGCTTATCTTCGAT-3'	
		Forward	5'-CTGACATGCAGCCAAAGC-3'	
		Reverse	5'-GTTTACCCTCGATGCTCTTGT-3'	
		Forward	5'-GGACACACAGAAGAATCCGT-3'	
		Reverse	5'-TCCCTACTCCATTGACTCTGAG-3'	
Mm. DHCR24	Mouse	Forward	5'-CGAAGAGGTAGCGGAAGATG-3'	
		Reverse	5'-AGAACTACCTGAAGACAAACCG-3'	
		Forward	5'-ACTGACATGCAGCCGAAG-3'	
		Reverse	5'-CACATTCACCTTGTACGCTCT-3'	
		Forward	5'-GACACATAAGAGGATTTCGAGAGC-3'	
		Reverse	5'-CCCTATTCCATTGACTCTGAGC-3'	

Hs. human, Mm. mouse.

Fig. 1 Effects of insulin on Akt phosphorylation in N2a and N2a-AβPP cells. A, N2a and N2a-AβPP cells were treated with vehicle (V) or insulin (INS) for 1 h at 0.1, 0.5, 1, and 5 nmol/L, and 1.72 μmol/L. Cellular proteins were resolved by SDS-PAGE, and pAkt-S473 (p.AKT), total Akt (T.AKT), and β-actin protein levels were

visualized by western blotting. B, Protein levels were quantified by densitometry, normalized to β-actin, and are presented relative to vehicle, which was set at 1 ($n = 3$; $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, two-tailed t -test). C, Signal intensities of p-Akt in N2a and N2a-AβPP cells.

using standard curves for each primer), 2 μL of primers at a final concentration of 500 nmol/L, and 6 μL DNase/RNase-free water at a final volume of 20 μL were prepared for QPCR and run using a CFX96 Real-time PCR detection system (Bio-Rad). The reactions were carried out using the 2stepAmp+melt program with the conditions 95°C/10 min, 55°C/30 s, go to step 2 39×, 95°C/10 min. The PCR efficiency was assessed by performing standard curves using pooled cDNA material and plotting the log of the starting quantity of the template against the Cq values to determine the equation of the linear regression line. Quantification of each target gene was normalized against the β-actin gene and the fold-change for each gene was calculated using vehicle as control.

Statistical Analysis

All results are reported as mean ± SEM. Statistical significance was analyzed using the unpaired two-tailed t -test for two-group comparisons or by one-way ANOVA with Bonferroni post-hoc tests for multiple-group comparisons. Statistical analysis for all experiments was performed using GraphPad Prism version 5 (La Jolla, CA, USA).

Results

Compromised Insulin Signaling and Inhibition of Insulin-Dependent Up-Regulation of Cholesterol-Synthesis Enzymes in N2a-AβPP Versus N2a Cells

The effects of Aβ on insulin signaling in the N2a-AβPP cell line expressing AβPP and producing Aβ peptides were

investigated by treating these cells and the parental N2a cells with insulin. N2a and N2a-AβPP cells were treated with insulin for 1 h at physiological concentrations 0.1, 0.5, and 1 nmol/L [33], higher concentration 5 nmol/L, and supra-physiological level 1.72 μmol/L. A comparison of the levels of insulin signaling in N2a and N2a-AβPP cells was carried out by visualizing the phosphorylation of Akt at S473 (pAkt) by western blot analysis (Fig. 1A). N2a cells displayed significant increases in pAkt at all insulin concentrations (Fig. 1B, left panel), while N2a-AβPP cells showed significant increases in the pAkt signal only at the higher concentrations of insulin (Fig. 1B, right panel). Accordingly, N2a-AβPP cells showed a significantly lower pAkt signal at all concentrations (except for 1.72 μmol/L) than the parental N2a cells (Fig. 1C). This indicates that insulin signaling is compromised in the N2a-AβPP cells, and suggests that insulin signaling is inhibited or interfered with in cells over-expressing AβPP and producing Aβ. Total Akt was also measured (Fig. 1A), and the levels were similar in both cell lines (data not shown).

To further support the finding that N2a-AβPP cells did not respond to physiological levels of insulin, N2a and N2a-AβPP cells were treated for up to 10 h with 0.1, 0.5, or 5 nmol/L insulin, and the expression levels of various cholesterol-synthesis genes were analyzed by QPCR. The SREBP2 gene expression level in N2a cells was significantly up-regulated from 1 h to 6 h, and was significantly down-regulated after 10 h of treatment at 0.1 and 0.5 nmol/L insulin (Fig. 2A, B, left panels). There was no significant change in SREBP2 expression in N2a-AβPP cells at these low concentrations (Fig. 2A, B, right panels), reflecting the poor response in insulin signaling as shown in Fig. 1. In

Fig. 2 Effects of insulin on the expression of cholesterol-synthesis genes in N2a and N2a-A β PP cells. N2a and N2a-A β PP cells were treated with 0.1, 0.5, and 5 nmol/L insulin (INS) or vehicle (V) for 1, 2, 4, 6, 8, and 10 h. Gene expression levels of SREBP2 (A–C), HMGCR (D–F), and DHCR24 (G–I) were determined by qPCR, normalized to β -actin, and are presented relative to vehicle, which was set to 1 ($n = 3$; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t -test).

cells treated with the higher concentration of 5 nmol/L insulin, the SREBP2 gene expression level was significantly up-regulated after 1, 2, and 4 h of treatment in N2a cells and after 1, 4, and 6 h in N2a-A β PP cells (Fig. 2C). Similarly, the HMGCR gene expression level was significantly up-regulated in N2a cells at all insulin concentrations after 6 and up to 10 h (Fig. 2D–F, left panels), but it was only up-regulated with 5 nmol/L insulin in N2a-A β PP cells after 4, 8 and 10 h of treatment (Fig. 2F, right panel). The expression level of HMGCR was not significantly increased at 0.1 or 0.5 nmol/L insulin after any treatment time in N2a-A β PP cells (Fig. 2 D, E, right panels). The DHCR24 gene expression level followed a similar trend, where the expression was significantly up-regulated in N2a cells at all insulin concentrations from 6 h up to 10 h (Fig. 2G–I, left panels), while it was only significantly up-regulated at 5 nmol/L in N2a-A β PP cells after 6 and 8 h of treatment (Fig. 2I, right panel). The expression level of DHCR24 was not significantly increased in N2a-A β PP cells with 0.1 or 0.5 nmol/L insulin at any treatment time (Fig. 2G, H, right panels). These results suggest that insulin resistance and the dysregulation of insulin-regulated cholesterol-metabolism genes occur in N2a-A β PP cells at physiological levels of insulin as compared to parental N2a cells.

Phosphorylation of IRS-1 at S612 Occurs in N2a-A β PP Cells at Basal Levels

Phosphorylation of IRS-1 at S612 represents the dysregulation of IRS activity [24, 25]. To determine how insulin signaling was dysregulated in N2a-A β PP cells at physiological levels of insulin, the phosphorylation state of IRS subunits was analyzed. N2a and N2a-A β PP cells were plated in serum-deprived medium for 24 h and cellular proteins were harvested for western blots (Fig. 3A). There was no significant difference in the levels of pAkt or pIRS-Y895 between N2a-A β PP and N2a cells (Fig. 3B), which indicated that there were no differences in insulin signaling between them. However, there was a significant increase in phosphorylation of IRS-1 at S612 in N2a-A β PP as compared to N2a cells. This suggests that IRS and the insulin signaling pathway are inhibited in N2a-A β PP cells.

Effects of Insulin on A β ₄₀ and A β ₄₂ Levels in N2a-A β PP Cells

The effects of insulin on A β metabolism were investigated in N2a and N2a-A β PP cells. The cells were treated with 5 nmol/L insulin for up to 8 h and the levels of A β ₄₀ and A β ₄₂ in the conditioned medium were determined by ELISA. A significant increase in A β ₄₀ and A β ₄₂ levels was found in the medium of N2a-A β PP cells at all treatment

times (Fig. 4A, B). As expected, A β was not detected in the parental N2a cell line since it does not express human A β PP (data not shown). The levels of A β in the medium increased in a time-dependent manner after treatment with insulin, showing that insulin promotes the secretion of A β . The ELISA kits were not sensitive enough to detect A β levels within the cells to note any differences and to rule out increased production versus secretion of A β .

A β ₄₂ Treatment of SH-SY5Y Cells Results in Phosphorylation of IRS-1 at S612 and c-Jun at S63 and Affects the Levels of Cholesterol-Synthesis Enzymes

In order to determine whether A β is a key factor causing insulin resistance in neural cells, SH-SY5Y cells were treated with 5 μ mol/L A β ₄₂ or scrambled A β ₄₂ (A β ₄₂sc) for 4, 6, and 10 h. Then the phosphorylation states of Akt, pIRS-S612, and c-Jun Ser63, as well as the levels of HMGCR and DHCR24 were determined by western blot analysis (Fig. 5A). The levels of pAkt did not change in treated cells versus controls (data not shown). The levels of pIRS-S612 were significantly higher in cells treated with A β ₄₂ for 6 and 10 h than in vehicle- or A β ₄₂sc-treated controls (Fig. 5B), suggesting a potential insulin-resistance effect in SH-SY5Y cells due to the presence of A β ₄₂. The pIRS-S612 levels were also significantly increased relative to vehicle control after 4 h of treatment in A β ₄₂- or A β ₄₂sc-treated SH-SY5Y cells (Fig. 5B), suggesting a peptide effect at 4 h. Furthermore, the levels of phosphorylated c-Jun Ser63 were significantly higher after 6 and 10 h of treatment than in both controls (Fig. 5C). As we reported previously, increased c-Jun phosphorylation indicates the activation of JNK and AP-1 [34]. The level of DHCR24 protein was significantly decreased in SH-SY5Y cells after treatment with A β ₄₂ for 4 and 6 h in comparison to both controls, and after 10 h in comparison to vehicle control (Fig. 5D). On the other hand, the level of HMGCR protein was significantly higher in response to 6 h of A β ₄₂ treatment than both controls (Fig. 5E). These results indicate that A β ₄₂ interferes with the levels of cholesterol-synthesis enzymes and cholesterol homeostasis in SH-SY5Y cells.

Insulin Signaling and Insulin-Dependent Up-Regulation of Cholesterol-Synthesis Enzymes in SH-SY5Y Cells

SH-SY5Y cells were treated for 1 h with insulin at 0.1, 0.5, 1, 5 nmol/L and 1.72 μ mol/L, and insulin signaling was verified by analyzing the phosphorylation of Akt at serine 473 by western blot analysis (Fig. 6A). The results showed

Fig. 3 N2a-A β PP cells exhibit higher IRS phosphorylation at S612 under basal conditions than N2a cells. (A) N2a and N2a-A β PP cells were plated in serum-free medium for 24 h and western blot was carried out for pAkt-S473 (p.AKT), pIRS-Y895, pIRS-S612, total IRS

(T.IRS), and β -actin. (B) The levels were quantified by densitometry, normalized to β -actin and are presented relative to N2a cells, which were set to 1 ($n = 3$; ** $P < 0.01$, two-tailed t -test).

Fig. 4 Effect of insulin treatment on the levels of A β_{40} and A β_{42} secreted by N2a-A β PP cells. N2a-A β PP cells were treated with 5 nmol/L insulin for up to 8 h. The levels of A β_{40} (A) and A β_{42} (B) in the conditioned medium were normalized to cellular protein content

and are presented relative to the average of vehicle at 2 h, which was set to 1 ($n = 3$; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t -test; + $P < 0.05$, ++ $P < 0.01$, +++ $P < 0.001$, one-way ANOVA).

Fig. 5 Effects of A β_{42} treatment on SH-SY5Y cells. SH-SY5Y cells were treated with vehicle (V), 5 μ mol/L A β_{42} (A β) or A β_{42} sc (Scr) for 4, 6, or 10 h. A, Cell proteins were harvested, resolved on SDS-PAGE, and the phosphorylation of IRS at S612 and c-Jun at S63, and the protein levels of DHCR24 and HMGCR were determined by

western blotting. B–E, The levels of these proteins were quantified by densitometry, normalized to β -actin, and are presented relative to vehicle, set to 1 ($n = 3$; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, one-way ANOVA).

a significant increase in Akt phosphorylation in cells treated with all doses of insulin as compared to cells treated with vehicle (Fig. 6B). There was no significant difference in total Akt levels between the cells treated with insulin or with vehicle (Fig. 6A). These data show that insulin signaling occurs in SH-SY5Y cells treated with insulin. The protein levels of HMGCR and DHCR24 were determined by western blotting after 8-h insulin treatment (Figure 6C). The levels of HMGCR protein were significantly up-regulated at all insulin concentrations, including physiological levels (0.1–1 nmol/L; Fig. 6D, left panel). Similarly, the levels of DHCR24 protein were significantly up-regulated at all insulin concentrations (Fig. 6D, right panel). The expression levels of the cholesterol-synthesis genes were also analyzed by QPCR at the same insulin concentrations after treatment from 1 to 10 h. After 1 h, there was a significant increase in SREBP2 gene expression level in cells treated with 0.1 to 5 nmol/L insulin and it continued to be upregulated for up to 2 h (Fig. 7A). Starting at 4 h, a significant decrease in SREBP2 gene expression occurred in cells treated with 5 nmol/L insulin, and at 6 h in cells treated with 0.1–1 nmol/L insulin (Fig. 7A). HMGCR gene expression was significantly increased at all insulin concentrations starting at 4 h and up to 10 h (Fig. 7B). Similarly, DHCR24 gene expression was significantly increased

at 0.1 nmol/L from 6 h to 10 h and at 0.5, 1, and 5 nmol/L from 4 h to 10 h (Fig. 7C). The up-regulation of cholesterol-synthesis enzymes mirrors the increased gene expression in response to insulin treatment at physiological levels.

Discussion

A number of studies have shown that AD brain is insulin-resistant and/or deficient in insulin signaling; this has been coined “Type III diabetes” [17, 35]. Insulin resistance or deficiency in insulin signaling may represent important mechanisms underlying the neuronal dysfunction and neurodegeneration leading to dementia [35]; however, the molecular mechanisms are still not completely understood. We used the *in vitro* models of N2a, N2a-A β PP, and SH-SY5Y cells to investigate whether A β PP and A β peptides are involved in the development of this phenotype. Treatment of SH-SY5Y and N2a cells with insulin showed that insulin activated insulin signaling in these cells (as shown by Akt phosphorylation) and stimulated the expression of cholesterol synthesis enzymes. However, N2a-A β PP cells, which overexpressed A β PP and produced A β_{40} and A β_{42} peptides, displayed an insulin-resistant phenotype relative

Fig. 6 Effects of insulin on Akt phosphorylation and cholesterol-synthesis enzymes in SH-SY5Y cells. A, B, SH-SY5Y cells were treated for 1 h with insulin at 0.1, 0.5, 1, and 5 nmol/L, and 1.72 μmol/L. Cell proteins were harvested and resolved by SDS-PAGE, and p-Akt at S473, total Akt, and β-actin protein levels were detected by western blotting (A). The levels of p-Akt were quantified by densitometry, normalized to β-actin, and are presented relative to vehicle, which was set to 1 ($n = 3$; * $P < 0.05$, *** $P < 0.001$, two-

tailed t -test) (B). C, D, SH-SY5Y cells were treated with insulin at the same concentrations as in (A) but for 8 h. The cell proteins were harvested and resolved by SDS-PAGE, and the protein levels of HMGCR and DHCR24 were analyzed by western blotting (C). The band intensities were quantified by densitometry, normalized to β-actin, and are presented relative to vehicle, which was set to 1 ($n = 3$; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t -test) (D).

Fig. 7 Cholesterol genes are upregulated by insulin treatment. SH-SY5Y cells were treated with 0.1, 0.5, 1, and 5 nmol/L insulin for 1, 2, 4, 6, 8, or 10 h. The mRNA was extracted, reverse-transcribed to cDNA, and QPCR analysis was performed for SREBP2 (A), HMGCR

(B), and DHCR24 (C). The levels were normalized to β -actin, and are presented relative to vehicle, which was set to 1 ($n = 3$; $*P < 0.05$, $**P < 0.01$, $***P < 0.001$, two-tailed t -test).

to parental N2a cells, as evidenced by reduced phosphorylation of Akt at S473 and disrupted insulin-dependent cholesterol-synthesis gene expression. It is attractive to speculate that the compromised insulin signaling in N2a-A β PP cells is due to the presence of A β peptides and/or A β PP. Increased phosphorylation of IRS-1 S612 in human neuroblastoma SH-SY5Y cells further substantiated that A β may cause insulin resistance. These results suggested that pIRS-1 S612 could be one of the sites of A β -induced insulin resistance in neural cells. Several mechanisms may be involved in the development of the insulin-resistant phenotype in these cells. A β peptides can cause c-Jun phosphorylation in SH-SY5Y cells as well as in human brain endothelial cells as we described previously [34, 36], indicating the activation of c-Jun N-terminal kinase (JNK). Activated JNK may associate with IRS-1 and inhibit the insulin-stimulated tyrosine phosphorylation of IRS-1 and thus block the downstream transmission of insulin signaling [37, 38]. SH-SY5Y cells treated with A β_{42} showed an increase in phosphorylation of c-Jun at serine 63, indicating activation of JNK and AP-1 for the pro-inflammatory response. Our previous study found that JNK-AP1 signaling is activated in the AD brain and in A β -treated brain endothelial cells, and is responsible for increased expression of inflammatory cytokines and chemokines [39]. Interestingly, activation of the pro-inflammatory response in SH-SY5Y cells post-A β treatment was in the same time-frame as pIRS-1 phosphorylation at S612, suggesting that A β -activated JNK and other events are involved in the

development of the insulin-resistant phenotype in these cells. A β peptides may also competitively bind to or interact with IRs [40], which desensitizes their response to insulin. All of these possibilities support the notion that overproduction or accumulation of A β peptides may be a primary cause of insulin resistance in neural cells.

A β dysregulated the expression of cholesterol-synthesis genes, not only in N2a-A β PP cells, but in SH-SY5Y cells as well. Treatment of SH-SY5Y cells with A β_{42} up-regulated the expression of HMGCR, which coincided with c-Jun phosphorylation in the cells. There is no report on the HMGCR levels in AD brain. HMGCR is a rate-limiting enzyme upstream in the mevalonate pathway that produces cholesterol and other isoprenoids [41]. The expression of genes for the proteins that are involved in isoprenoid synthesis, along with isoprenoids themselves, have been reported to be elevated in the frontal cortex of AD patients [42, 43] and have been implicated in inflammation and oxidative stress [44–46]. HMGCR inhibitors (such as statins) have been shown to reduce A β generation by depleting isoprenoids independent of cholesterol levels [47–49]. This suggests that up-regulation of HMGCR in SH-SY5Y cells by A β_{42} may increase the isoprenoid levels for an inflammatory response. DHCR24, also known as selective AD indicator 1 (seladin 1), is a multifunctional protein due to its enzymatic, antioxidant, anti-apoptotic, and neuroprotective activities [50, 51], and is ubiquitously expressed in endocrine glands and in the brain [52]. DHCR24 is down-regulated in AD-vulnerable brain

regions such as the inferior temporal cortex [52, 53], and the enzyme has been shown to protect neurons from A β -mediated toxicity and to decrease A β ₄₂ production by counteracting the β -secretase cleavage of A β PP [54, 55]. Moreover, DHCR24-dependent cholesterol synthesis reduces the membrane aggregate interaction and cell damage associated with amyloid treatment [56]. Thus, our results of decreased DHCR24 protein levels in SH-SY5Y cells in response to A β ₄₂ treatment are consistent with the literature. A β ₄₂ increased HMGCR expression and decreased DHCR24 expression in SH-SY5Y cells, which may lead to dysregulation of the cholesterol-synthesis pathway or cholesterol homeostasis, an increased inflammatory response, and decreased neuroprotection. Overall, A β ₄₂ induces pro-inflammatory c-Jun phosphorylation and HMGCR expression and down-regulates the expression of neuroprotective/anti-inflammatory DHCR24 in SH-SY5Y cells.

Interestingly, treatment of N2a-A β PP cells with insulin (5 nmol/L) increased the levels of A β ₄₀ and A β ₄₂ in the medium, in line with other studies [57, 58]. It has been reported that insulin-induced release of A β into the culture medium can reduce the intracellular accumulation of the peptide [58]. The release of A β into the extracellular compartment can lead to its degradation by membrane-associated and secreted insulin-degrading enzymes [59] or A β clearance. Along with increasing A β secretion into the medium, insulin favors α -secretase activity with increased neurotrophic action, inhibits the translocation of the A β PP intracellular domain into the nucleus, and phosphorylates GSK3 β , inhibiting its enzymatic activity for reduced tau pathology [60]. Studies have also shown that insulin inhibits the nuclear activity of the A β PP intracellular domain, reduces the transcription of genes that encode pro-amyloidogenic enzymes such as β -secretase and GSK3 β , and increases the transcription of anti-amyloidogenic enzymes such as α -secretase and insulin-degrading enzyme [60, 61]. Our results together with those of others suggest that enhancing insulin signaling can relieve insulin resistance, have positive effects on the suppressed cholesterol metabolism of neural cells, and promote A β release from the cells.

In summary, the results of this study demonstrated that A β may be a primary cause of developing an insulin-resistant phenotype in N2a-A β PP and SH-SY5Y cells as manifested by decreased response to insulin treatment, increased IRS-1 inhibition, and dysregulation of cholesterol-synthesis gene expression. Another study has provided direct evidence that intraneuronal expression of A β ₄₂ inhibits both insulin-induced Akt phosphorylation and activity [62]. In addition, A β induced c-Jun phosphorylation and the expression of pro-inflammatory HMGCR, as well as inhibiting the expression of anti-inflammatory/

neuroprotective DHCR24. All of these conditions dysregulate the function and metabolism of neural cells. Enhancement of insulin signaling by higher concentrations of insulin relieved the insulin-resistant phenotype and the dysregulated cholesterol synthesis pathway, increased the release of A β peptides from cells into the extracellular compartment, and inhibited the pro-inflammatory response. Alleviation of insulin resistance in AD brain may be a future direction of therapeutic development to relieve or delay the progression of the disease and neurodegeneration.

Acknowledgements This work was supported by CIHR Grants (109606, 106886, and TAD 125698) and an Ontario Graduate Scholarship, an Admission Scholarship, and an Excellence Scholarship from the University of Ottawa. This work was conducted at the National Research Council of Canada. We thank Dr. Hsiao-Huei Chen and Dr. Ross Milne at the University of Ottawa for their critical comments and support of the study, and Dr. Huaxi Xu at the Sanford-Burnham Medical Research Institute for providing the N2a-A β PP cells.

References

1. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, *et al.* Inflammation and Alzheimer's disease. *Neurobiol Aging* 2000, 21: 383–421.
2. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM. Forecasting the global burden of Alzheimer's disease. *Alzheimers Dement* 2007, 3: 186–191.
3. De Felice FG. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. *J Clin Invest* 2013, 123: 531–539.
4. Xiong H, Callaghan D, Jones A, Walker DG, Lue LF, Beach TG, *et al.* Cholesterol retention in Alzheimer's brain is responsible for high beta- and gamma-secretase activities and Abeta production. *Neurobiol Dis* 2008, 29: 422–437.
5. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. *Physiol Rev* 2001, 81: 741–766.
6. Soriano S, Lu DC, Chandra S, Pietrzik CU, Koo EH. The amyloidogenic pathway of amyloid precursor protein (APP) is independent of its cleavage by caspases. *J Biol Chem* 2001, 276: 29045–29050.
7. Gouras GK, Tsai J, Naslund J, Vincent B, Edgar M, Checler F, *et al.* Intraneuronal Abeta42 accumulation in human brain. *Am J Pathol* 2000, 156: 15–20.
8. LaFerla FM, Green KN, Oddo S. Intracellular amyloid-beta in Alzheimer's disease. *Nat Rev Neurosci* 2007, 8: 499–509.
9. Annaert W, De Strooper B. A cell biological perspective on Alzheimer's disease. *Annu Rev Cell Dev Biol* 2002, 18: 25–51.
10. Sato M, Murakami K, Uno M, Nakagawa Y, Katayama S, Akagi K, *et al.* Site-specific inhibitory mechanism for amyloid beta42 aggregation by catechol-type flavonoids targeting the Lys residues. *J Biol Chem* 2013, 288: 23212–23224.
11. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. *Nat Rev Mol Cell Biol* 2007, 8: 101–112.
12. Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and Alzheimer's disease. *Rev Neurosci* 2014, 25: 509–525.
13. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, *et al.* Role for neuronal insulin resistance in neurodegenerative diseases. *Proc Natl Acad Sci USA* 2004, 101: 3100–3105.

14. Bomfim TR, Forny-Germano L, Sathler LB, Brito-Moreira J, Houzel JC, Decker H, *et al.* An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer's disease-associated Abeta oligomers. *J Clin Invest* 2012, 122: 1339–1353.
15. Takeda S, Sato N, Uchio-Yamada K, Sawada K, Kunieda T, Takeuchi D, *et al.* Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. *Proc Natl Acad Sci USA* 2010, 107: 7036–7041.
16. Salkovic-Petrisic M, Hoyer S. Central insulin resistance as a trigger for sporadic Alzheimer-like pathology: an experimental approach. *J Neural Transm Suppl* 2007: 217–233.
17. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, *et al.* Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease—is this type 3 diabetes? *J Alzheimers Dis* 2005, 7: 63–80.
18. Craft S. Alzheimer disease: insulin resistance and AD—extending the translational path. *Nat Rev Neurol* 2012, 8: 360–362.
19. Burgering BM, Coffey PJ. Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. *Nature* 1995, 376: 599–602.
20. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, *et al.* The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. *Cell* 1995, 81: 727–736.
21. Sun XJ, Miralpeix M, Myers MG, Jr., Glasheen EM, Backer JM, Kahn CR, *et al.* Expression and function of IRS-1 in insulin signal transmission. *J Biol Chem* 1992, 267: 22662–22672.
22. Myers MG, Jr., Sun XJ, Cheatham B, Jachna BR, Glasheen EM, Backer JM, *et al.* IRS-1 is a common element in insulin and insulin-like growth factor-I signaling to the phosphatidylinositol 3'-kinase. *Endocrinology* 1993, 132: 1421–1430.
23. Wang LM, Myers MG, Jr., Sun XJ, Aaronson SA, White M, Pierce JH. IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. *Science* 1993, 261: 1591–1594.
24. Ozes ON, Akca H, Mayo LD, Gustin JA, Maehama T, Dixon JE, *et al.* A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. *Proc Natl Acad Sci USA* 2001, 98: 4640–4645.
25. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. *Biochemistry* 1997, 36: 12939–12947.
26. D'Alessandris C, Lauro R, Presta I, Sesti G. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser307 and Ser 612 in L6 myocytes, thereby impairing the insulin signalling pathway that promotes glucose transport. *Diabetologia* 2007, 50: 840–849.
27. Avramoglu RK, Basciano H, Adeli K. Lipid and lipoprotein dysregulation in insulin resistant states. *Clin Chim Acta* 2006, 368: 1–19.
28. Suzuki R, Lee K, Jing E, Biddinger SB, McDonald JG, Montine TJ, *et al.* Diabetes and insulin in regulation of brain cholesterol metabolism. *Cell Metab* 2010, 12: 567–579.
29. Bonzon-Kulichenko E, Schwudke D, Gallardo N, Molto E, Fernandez-Agullo T, Shevchenko A, *et al.* Central leptin regulates total ceramide content and sterol regulatory element binding protein-1C proteolytic maturation in rat white adipose tissue. *Endocrinology* 2009, 150: 169–178.
30. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. *Proc Natl Acad Sci USA* 1999, 96: 11041–11048.
31. Goldstein JL, Rawson RB, Brown MS. Mutant mammalian cells as tools to delineate the sterol regulatory element-binding protein pathway for feedback regulation of lipid synthesis. *Arch Biochem Biophys* 2002, 397: 139–148.
32. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. *J Clin Invest* 2002, 109: 1125–1131.
33. Li G, Barrett EJ, Wang H, Chai W, Liu Z. Insulin at physiological concentrations selectively activates insulin but not insulin-like growth factor I (IGF-I) or insulin/IGF-I hybrid receptors in endothelial cells. *Endocrinology* 2005, 146: 4690–4696.
34. Vukic V, Callaghan D, Walker D, Lue LF, Liu QY, Couraud PO, *et al.* Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. *Neurobiol Dis* 2009, 34: 95–106.
35. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. *J Diabetes Sci Technol* 2008, 2: 1101–1113.
36. Bamji-Mirza M, Callaghan D, Najem D, Shen S, Hasim MS, Yang Z, *et al.* Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-beta-induced signaling dysregulation and inflammatory response. *J Alzheimers Dis* 2014, 40: 105–122.
37. Aguirre V, Uchida T, Yenush L, Davis R, White MF. The c-Jun NH(2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser(307). *J Biol Chem* 2000, 275: 9047–9054.
38. Kaneto H. The JNK pathway as a therapeutic target for diabetes. *Expert Opin Ther Targets* 2005, 9: 581–592.
39. Pratico D, Trojanowski JQ. Inflammatory hypotheses: novel mechanisms of Alzheimer's neurodegeneration and new therapeutic targets? *Neurobiol Aging* 2000, 21: 441–445; discussion 451–443.
40. Xie L, Helmerhorst E, Taddei K, Plewright B, Van Bronswijk W, Martins R. Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. *J Neurosci* 2002, 22: RC221.
41. Brown MS, Goldstein JL. Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. *J Lipid Res* 1980, 21: 505–517.
42. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP. Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production. *Mol Neurobiol* 2010, 41: 341–350.
43. Hooff GP, Wood WG, Muller WE, Eckert GP. Isoprenoids, small GTPases and Alzheimer's disease. *Biochim Biophys Acta* 2010, 1801: 896–905.
44. Cole SL, Vassar R. Isoprenoids and Alzheimer's disease: a complex relationship. *Neurobiol Dis* 2006, 22: 209–222.
45. Linseman DA, Loucks FA. Diverse roles of Rho family GTPases in neuronal development, survival, and death. *Front Biosci* 2008, 13: 657–676.
46. Gelb MH, Brunsvelde L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, *et al.* Therapeutic intervention based on protein prenylation and associated modifications. *Nat Chem Biol* 2006, 2: 518–528.
47. Won J-S, Im Y-B, Khan M, Contreras M, Singh AK, Singh I. Lovastatin inhibits amyloid precursor protein (APP) β -cleavage through reduction of APP distribution in Lubrol WX extractable low density lipid rafts. *Journal of Neurochemistry* 2008, 105: 1536–1549.
48. Ostrowski SM, Wilkinson BL, Golde TE, Landreth G. Statins Reduce Amyloid- β Production through Inhibition of Protein Isoprenylation. *Journal of Biological Chemistry* 2007, 282: 26832–26844.

49. Tamboli IY, Barth E, Christian L, Siepmann M, Kumar S, Singh S, *et al.* Statins Promote the Degradation of Extracellular Amyloid β -Peptide by Microglia via Stimulation of Exosome-associated Insulin-degrading Enzyme (IDE) Secretion. *Journal of Biological Chemistry* 2010, 285: 37405–37414.
50. Drzewinska J, Pulaski L, Soszynski M, Bartosz G. [Seladin-1/DHCR24: a key protein of cell homeostasis and cholesterol biosynthesis]. *Postepy Hig Med Dosw (Online)* 2009, 63: 318–330.
51. Lu X, Kambe F, Cao X, Kozaki Y, Kaji T, Ishii T, *et al.* 3beta-Hydroxysteroid-delta24 reductase is a hydrogen peroxide scavenger, protecting cells from oxidative stress-induced apoptosis. *Endocrinology* 2008, 149: 3267–3273.
52. Greeve I, Hermans-Borgmeyer I, Brellinger C, Kasper D, Gomez-Isla T, Behl C, *et al.* The human DIMINUTO/DWARF1 homolog seladin-1 confers resistance to Alzheimer's disease-associated neurodegeneration and oxidative stress. *J Neurosci* 2000, 20: 7345–7352.
53. Sarajarvi T, Haapasalo A, Viswanathan J, Makinen P, Laitinen M, Soininen H, *et al.* Down-regulation of seladin-1 increases BACE1 levels and activity through enhanced GGA3 depletion during apoptosis. *J Biol Chem* 2009, 284: 34433–34443.
54. Cramer A, Biondi E, Kuehnle K, Lutjohann D, Thelen KM, Perga S, *et al.* The role of seladin-1/DHCR24 in cholesterol biosynthesis, APP processing and A β generation in vivo. *EMBO J* 2006, 25: 432–443.
55. Lamsa R, Helisalmi S, Hiltunen M, Herukka SK, Tapiola T, Pirttila T, *et al.* The association study between DHCR24 polymorphisms and Alzheimer's disease. *Am J Med Genet B Neuropsychiatr Genet* 2007, 144B: 906–910.
56. Cecchi C, Rosati F, Pensalfini A, Formigli L, Nosi D, Liguri G, *et al.* Seladin-1/DHCR24 protects neuroblastoma cells against A β toxicity by increasing membrane cholesterol content. *J Cell Mol Med* 2008, 12: 1990–2002.
57. Solano DC, Sironi M, Bonfini C, Solerte SB, Govoni S, Racchi M. Insulin regulates soluble amyloid precursor protein release via phosphatidylinositol 3 kinase-dependent pathway. *The FASEB Journal* 2000, 14: 1015–1022.
58. Gasparini L, Gouras GK, Wang R, Gross RS, Beal MF, Greengard P, *et al.* Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. *J Neurosci* 2001, 21: 2561–2570.
59. Vekrellis K, Ye Z, Qiu WQ, Walsh D, Hartley D, Chesneau V, *et al.* Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. *J Neurosci* 2000, 20: 1657–1665.
60. Pandini G, Pace V, Copani A, Squatrito S, Milardi D, Vigneri R. Insulin has multiple anti-amyloidogenic effects on human neuronal cells. *Endocrinology* 2013, 154: 375–387.
61. Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, *et al.* Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. *Proc Natl Acad Sci USA* 2003, 100: 4162–4167.
62. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW. The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. *Mol Biol Cell* 2009, 20: 1533–1544.